Lineage Cell Therapeutics, Inc. Payments for Repurchase of Initial Public Offering
Lineage Cell Therapeutics, Inc. (LCTX) reported Payments for Repurchase of Initial Public Offering of $174.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2023-08-10
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-12-31 was $11.00K, a 90.91% decline year-over-year.
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-09-30 was $38.00K, a 63.11% decline year-over-year.
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-12-31 was $121.00K.
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-09-30 was $103.00K.
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2022 was $106.00K, a 90.37% decline from fiscal 2021.
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2021 was $1.10M, a 209.27% increase from fiscal 2020.
- Lineage Cell Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2020 was $356.00K.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2023-06-30 | $174.00K 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $49.00K derived: sum of 2 quarters · filed 2023-03-09 | $106.00K 10-K · filed 2023-03-09 | |
| 2022-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $95.00K 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $57.00K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $224.00K derived: sum of 2 quarters · filed 2023-03-09 | $487.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.10M 10-K · filed 2023-03-09 |
| 2021-09-30 | $103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $366.00K derived: sum of 2 quarters · filed 2022-11-10 | $980.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $877.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $614.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $356.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |